Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Other Non-Current Liabilities (2019 - 2025)

Karyopharm Therapeutics (KPTI) has disclosed Other Non-Current Liabilities for 8 consecutive years, with $11.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Non-Current Liabilities rose 356.58% year-over-year to $11.1 million, compared with a TTM value of $11.1 million through Dec 2025, up 356.58%, and an annual FY2025 reading of $11.1 million, up 356.58% over the prior year.
  • Other Non-Current Liabilities was $11.1 million for Q4 2025 at Karyopharm Therapeutics, down from $73.5 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $133.0 million in Q4 2021 and bottomed at $978000.0 in Q4 2023.
  • Average Other Non-Current Liabilities over 5 years is $65.8 million, with a median of $73.5 million recorded in 2024.
  • The sharpest move saw Other Non-Current Liabilities tumbled 99.26% in 2023, then soared 2746.59% in 2025.
  • Year by year, Other Non-Current Liabilities stood at $133.0 million in 2021, then dropped by 0.21% to $132.7 million in 2022, then crashed by 99.26% to $978000.0 in 2023, then surged by 148.47% to $2.4 million in 2024, then soared by 356.58% to $11.1 million in 2025.
  • Business Quant data shows Other Non-Current Liabilities for KPTI at $11.1 million in Q4 2025, $73.5 million in Q3 2025, and $8.3 million in Q2 2025.